http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77d5a5296626f2b201079065cfb6e3b8
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Miller |
| name | Langdon L Miller Langdon L. Miller |
| given-name | Langdon L Langdon L. |
| organization-name | Pharmacia Corporation, Peapack, New Jersey, USA From the Frederick Cancer Research and Development Center, Biological Response Modifiers Program, National Cancer Institute, and Clinical Services Program, SAIC Frederick, NCI-FCRDC, both of Frederick, MD; the Biometric Research Branch and the Investigational Drug Branch, both of the Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and the Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR. Gilead Sciences, Seattle, WA; and From the H. Lee Moffitt Cancer Center, University of South Florida, Gastrointestinal Program Office, Tampa, FL; University of Massachusetts Medical Center, Worcester, MA; Mt Sinai Medical Center, New York, NY; University of Minnesota, Research Services Organization, Minneapolis, MN; St John’s Mercy Medical Center, St Louis, MO; Tennessee Oncology, Nashville, and Boston Cancer Group, Memphis, TN; Lakeland Medical Center, St Joseph, MI; Scripps Clinic, Ida M. and Cecil H. Green Cancer Center; La Jolla, and... Gilead Sciences, Inc., Seattle, WA; and From the University of Texas Health Science Center at San Antonio, San Antonio, TX; Pharmacia & Upjohn Company, Kalamazoo, MI; Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX; and Brooke Army Medical Center, Ft. Sam Houston, TX VelosBio, San Diego, CA From the University of North Carolina, Chapel Hill, NC; Indiana University, Indianapolis, IN; Pharmacia Corp, Peapack, NJ; University of Southern California/Norris Cancer Center, and Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacia Corp, Milan, Italy. Gilead Sciences Inc, Seattle, WA; 7Pfizer Corporation, New York, New York; and From the Frederick Cancer Research and Development Center, Biological Response Modifiers Program, National Cancer Institute, Frederick, MD; the Biometric Research Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; the Clinical Services Program, SAIC Frederick, Frederick, MD; Immunex Research and Development Corp, Seattle, WA. From the Vanderbilt University, Nashville, TN; Duke University, Durham, NC; University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; The Cancer Treatment and Research Center, San Antonio, TX; and Pharmacia & Upjohn, Kalamazoo, MI. From the Departments of Surgery, Medicine, Pediatrics, Radiology, and Pathology, Duke University Medical Center, Durham, NC; Pharmacia & Upjohn, Kalamazoo, MI; Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN; and Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA; email fried003@mc.duke.edu. From the UniversitätsklinikFrankfurt, Germany; Istituto Nazionale Tumori, Milan, Italy; Sint-Augustinus Ziekenhuis, Antwerpen, Belgium; Centro Oncologico de Rosario, Santa Fe, Argentina; Physicians Reliance Network Research, Baylor-Sammons Cancer Center, Dallas, Texas; Institute of Oncology, Ljubljana, Slovenia; and Pharmacia & Upjohn, Italy and United States. Calistoga Pharmaceuticals Inc, Seattle, WA From the University of Miami and Sylvester Cancer Center, Miami, FL; Medical University of South Carolina, Charleston, SC; US Oncology, Dallas, TX; Pfizer Corporation, New York, NY; Jewish General Hospital, Montreal, Quebec, Canada; Christchurch Hospital, Christchurch, New Zealand; and Pharmacia Italy SPA, Pfizer Group, Nerviano, Italy VelosBio, Inc, San Diego, CA; Gilead Sciences, Foster City, CA From the International Drug Development Institute, Louvain-la-Neuve; Center for Statistics, Hasselt University, Diepenbeek, Belgium; Oncology Therapy Area, AstraZeneca Research and Development, Macclesfield, United Kingdom; Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif; Oncology Therapy Area, AstraZeneca, Rueil Malmaison, France; Division of Biostatistics, Mayo Clinic, Rochester, MN; and PTC Therapeutics, South Plainfield, NJ |
Incoming Links
Total number of triples: 73.